These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 3135160

  • 1. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
    Levy J.
    Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
    [Abstract] [Full Text] [Related]

  • 2. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S, Waters V, Jahnke N, Ratjen F.
    Cochrane Database Syst Rev; 2020 Jun 10; 6(6):CD009528. PubMed ID: 32520436
    [Abstract] [Full Text] [Related]

  • 3. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V, Ratjen F.
    Cochrane Database Syst Rev; 2015 Mar 05; (3):CD009528. PubMed ID: 25741986
    [Abstract] [Full Text] [Related]

  • 4. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V, Ratjen F.
    Cochrane Database Syst Rev; 2012 Nov 14; 11():CD009528. PubMed ID: 23152277
    [Abstract] [Full Text] [Related]

  • 5. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A.
    Lancet; 2012 Nov 14; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract] [Full Text] [Related]

  • 6. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN, Ratjen F.
    Semin Respir Crit Care Med; 2009 Oct 14; 30(5):587-95. PubMed ID: 19760546
    [Abstract] [Full Text] [Related]

  • 7. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
    Ratjen F.
    Int J Antimicrob Agents; 2001 Feb 14; 17(2):93-6. PubMed ID: 11165111
    [Abstract] [Full Text] [Related]

  • 8. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P, Whitaker P, Peckham D.
    Curr Med Res Opin; 2012 Jun 14; 28(6):1059-67. PubMed ID: 22401602
    [Abstract] [Full Text] [Related]

  • 9. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS, Sherrard LJ, Kidd TJ, Ramsay KA, Buckley C, Syrmis M, Grimwood K, Bell SC, Whiley DM.
    BMC Pulm Med; 2017 Nov 02; 17(1):138. PubMed ID: 29096618
    [Abstract] [Full Text] [Related]

  • 10. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G, Campana S, Festini F, Mascherini M, Döring G.
    Eur Respir J; 2005 Sep 02; 26(3):458-61. PubMed ID: 16135728
    [Abstract] [Full Text] [Related]

  • 11. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
    Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM.
    Expert Rev Respir Med; 2015 Feb 02; 9(1):13-22. PubMed ID: 25417708
    [Abstract] [Full Text] [Related]

  • 12. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct 02; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O, Tolker-Nielsen T, Jensen PØ, Wang H, Høiby N.
    Adv Drug Deliv Rev; 2015 May 02; 85():7-23. PubMed ID: 25477303
    [Abstract] [Full Text] [Related]

  • 14. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ, Green JL, Maurer BA, Kolter R.
    Environ Microbiol; 2010 May 02; 12(5):1293-303. PubMed ID: 20192960
    [Abstract] [Full Text] [Related]

  • 15. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G, Petraru E, Dahorea C, Anton DT.
    Rev Med Chir Soc Med Nat Iasi; 2012 May 02; 116(2):580-7. PubMed ID: 23077957
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial therapy against Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas cepacia.
    Geddes DM.
    Chest; 1988 Aug 02; 94(2 Suppl):140S-145S. PubMed ID: 3293940
    [Abstract] [Full Text] [Related]

  • 17. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA, Rigo A, Bonazzi L, Zanolla L, Mastella G.
    Acta Univ Carol Med (Praha); 1990 Aug 02; 36(1-4):44-5. PubMed ID: 2130717
    [Abstract] [Full Text] [Related]

  • 18. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M, Nazareth D, Walshaw M.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 02; 27(4):299-305. PubMed ID: 24219814
    [Abstract] [Full Text] [Related]

  • 19. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE, KB001 Study Group.
    Pediatr Pulmonol; 2014 Jul 02; 49(7):650-8. PubMed ID: 24019259
    [Abstract] [Full Text] [Related]

  • 20. Rational parameters for antibiotic therapy in patients with cystic fibrosis.
    Govan JR, Doherty C, Glass S.
    Infection; 1987 Jul 02; 15(4):300-7. PubMed ID: 3117704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.